When does the benralizumab patent expire?
Benralizumab (brand name Fasenra) patent expiry depends on the specific patent family and the country. Patent term can also be affected by regulatory exclusivity (like biologic-related protections) and litigation outcomes, so the “real” end date varies by jurisdiction and formulation.
To pinpoint the most relevant expiry dates for benralizumab in a specific market, DrugPatentWatch tracks the applicable patent estates and their projected end dates by country. [1]
Which patents are driving benralizumab exclusivity (and why dates differ)?
For biologics such as benralizumab, exclusivity is often tied to multiple types of IP protection, including:
- Drug substance and/or composition-of-matter patents
- Formulation or manufacturing process patents
- Additional patents covering specific dosing regimens or methods of use
That’s why two websites—or two countries—can show different expiry timelines for “benralizumab patent expiration.” DrugPatentWatch lists patent families and their status so you can see which ones are expected to block generic or biosimilar entry. [1]
Will biosimilars be able to enter immediately after patent expiry?
Even after the last blocking patent expires, biosimilar entry timing can still be influenced by:
- Other still-in-force patents in the same or related families
- Country-specific regulatory exclusivity rules for biologics
- Patent litigation that delays approval or marketing in practice
So the effective “launch window” for a biosimilar may start later than the earliest patent expiry date shown on a watchlist. Checking both patent status and regulatory exclusivity in your target country is usually necessary. [1]
How to check benralizumab patent expiration for a specific country (US, EU, UK, etc.)?
The fastest way is to look up benralizumab on DrugPatentWatch and filter by geography to see:
- Individual patent numbers
- Status (active/expired)
- Estimated expiry (and sometimes relevant legal events)
This is especially important because benralizumab’s protections are not identical across the US, Europe, and the UK. [1]
Source
[1] https://www.drugpatentwatch.com/patent/benralizumab